MedTrace Logo

GnRH Agonist Pretreatment in Hysteroscopic Myomectomy

NCT01873378 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2015-08-11

No results posted yet for this study

Summary

The primary outcome of this study is to assess if the GnRHa administration before cold loop hysteroscopic myomectomy contributes to accomplish the treatment in only one surgical procedure. Moreover, we will investigate the intraoperative influence of such pharmacologic therapy in terms of distension liquid absorption and duration of the procedures.

Conditions

  • Uterine Myoma

Interventions

DRUG

Triptorelin 3.75 mg

Sponsors & Collaborators

  • Azienda Ospedaliera S. Maria della Misericordia

    lead OTHER

Principal Investigators

  • sandro gerli, MD · University of Perugia, Perugia, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01873378 on ClinicalTrials.gov